Third coronavirus vaccine registered in Russia

Federal Research Center for Research and Development of Immunobiological Preparations M.P. Chumakov, on February 20, 2021, he received a registration certificate from the Ministry of Health for the KoviVac vaccine, developed to prevent coronavirus infection COVID-19. In mid-March 2021, it is planned to put into circulation the first 120 thousand doses of the vaccine.
CoviVac refers to whole virion inactivated vaccines, that is, using a whole virus. According to the general director of the Chumakov Center, Aydar Ishmukhametov, none of the international companies working on this method of obtaining vaccines has yet released whole virion vaccines against COVID-19. “I am absolutely sure that six months later, maybe earlier, all the same, whole-virion vaccines will dominate in the same way as it happened in other types of vaccines, in other developments,” he said.

Clinical studies of the KoviVac vaccine were held in 2020 in Novosibirsk, St. Petersburg and Kirov, 400 people took part in them. The vaccine is recommended for use from 18 to 60 years old.

“Already in mid-March, the first 120,000 doses will be put into civilian circulation,” noted Russian Prime Minister Mikhail Mishustin.

In the registration certificate, only the Chumakov Center is indicated as a manufacturer. According to Deputy Prime Minister Tatyana Golikova, representatives of the center “will soon present their proposals on scaling up the vaccine.” Mishustin twice stressed that scaling up production should not affect quality.

Expansion of indications for use will be possible after the passage of phase II clinical trials with the participation of volunteers over 60 years of age and volunteers with concomitant diseases; phase III clinical trials are planned for March 2021.

The world’s first vaccine against coronavirus infection Sputnik V was registered by the Research Center for Epidemiology and Microbiology. N.F. Gamalei on August 11, 2020.

The second Russian vaccine against coronavirus – EpiVacCorona, developed by the State Scientific Center for Virology and Biotechnology “Vector”, was registered in October 2020.

According to Mishustin, more than 10 million doses of Sputnik V vaccine have been produced, about 80 thousand doses of EpiVacCorona. By the end of the first half of 2021, the production of Sputnik V and EpiVacCorona vaccines will amount to 88 million dose kits (of which 83 million are Sputnik V), Golikova said. For vaccination in Russia in the first half of the year, 59 million dose kits will be available, while 7.9 million kits have been released for use by the population.

The government, together with Rospotrebnadzor, the Ministry of Health and experts, worked out and recommended for use a mathematical model for achieving herd immunity, in accordance with this model, the vaccine will be distributed across the regions, added the Deputy Prime Minister.